NO20025132L - Natrium-hydrogen-byttertype 1-inhibitor (NHE-1) - Google Patents

Natrium-hydrogen-byttertype 1-inhibitor (NHE-1)

Info

Publication number
NO20025132L
NO20025132L NO20025132A NO20025132A NO20025132L NO 20025132 L NO20025132 L NO 20025132L NO 20025132 A NO20025132 A NO 20025132A NO 20025132 A NO20025132 A NO 20025132A NO 20025132 L NO20025132 L NO 20025132L
Authority
NO
Norway
Prior art keywords
nhe
inhibitor
sodium
exchanger type
hydrogen exchanger
Prior art date
Application number
NO20025132A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025132D0 (no
Inventor
Weichao George Chen
Eric David Cox
Angel Guzman-Perez
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20025132D0 publication Critical patent/NO20025132D0/no
Publication of NO20025132L publication Critical patent/NO20025132L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20025132A 2000-04-28 2002-10-25 Natrium-hydrogen-byttertype 1-inhibitor (NHE-1) NO20025132L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20043200P 2000-04-28 2000-04-28
PCT/IB2001/000277 WO2001083470A1 (en) 2000-04-28 2001-02-28 Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)

Publications (2)

Publication Number Publication Date
NO20025132D0 NO20025132D0 (no) 2002-10-25
NO20025132L true NO20025132L (no) 2002-12-12

Family

ID=22741697

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025132A NO20025132L (no) 2000-04-28 2002-10-25 Natrium-hydrogen-byttertype 1-inhibitor (NHE-1)

Country Status (40)

Country Link
EP (1) EP1276737A1 (pl)
JP (1) JP2003531900A (pl)
KR (1) KR20020093079A (pl)
CN (1) CN1225466C (pl)
AP (1) AP2002002651A0 (pl)
AR (1) AR028375A1 (pl)
AU (1) AU2001235896A1 (pl)
BG (1) BG107139A (pl)
BR (1) BR0110268A (pl)
CA (1) CA2407535A1 (pl)
CO (1) CO5221125A1 (pl)
CR (1) CR6797A (pl)
CZ (1) CZ20023408A3 (pl)
DZ (1) DZ3310A1 (pl)
EA (1) EA004882B1 (pl)
EE (1) EE200200615A (pl)
GT (1) GT200100064A (pl)
HN (1) HN2001000042A (pl)
HR (1) HRP20020851A2 (pl)
HU (1) HUP0300651A2 (pl)
IL (1) IL152075A0 (pl)
IS (2) IS6567A (pl)
MA (1) MA26897A1 (pl)
MX (1) MXPA02010600A (pl)
MY (1) MY133842A (pl)
NO (1) NO20025132L (pl)
NZ (1) NZ521348A (pl)
OA (1) OA12256A (pl)
PA (1) PA8513301A1 (pl)
PE (1) PE20011270A1 (pl)
PL (1) PL357765A1 (pl)
SK (1) SK14872002A3 (pl)
SV (1) SV2002000418A (pl)
TN (1) TNSN01065A1 (pl)
TR (1) TR200202439T2 (pl)
UA (1) UA73348C2 (pl)
UY (1) UY26680A1 (pl)
WO (1) WO2001083470A1 (pl)
YU (1) YU79602A (pl)
ZA (1) ZA200208605B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355899A1 (en) * 2001-01-31 2003-10-29 Pfizer Products Inc. Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
CA2469305A1 (en) * 2001-12-19 2003-06-26 Frank Robert Busch Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
WO2003092694A1 (en) * 2002-05-02 2003-11-13 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors
FR2840302B1 (fr) * 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
ES2220185B1 (es) * 2002-07-16 2006-04-01 Consejo Sup. De Investig. Cientificas Nuevo peptido inhibidor del intercambiador na+/h+ (pinhe), y sus aplicaciones.
MXPA05008612A (es) * 2003-02-14 2005-12-05 Smithkline Beecham Corp Compuestos novedosos.
RU2518741C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ГАЛОГЕНИДЫ 1-ДИАЛКИЛАМИНОЭТИЛ-3-[ЗАМЕЩЕННЫЙ(ДИЗАМЕЩЕННЫЙ) ФЕНАЦИЛ]-2-АМИНОБЕНЗИМИДАЗОЛИЯ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU46200A (sh) * 1998-02-27 2003-02-28 Pfizer Products Inc. N-(supstituisani peto-članog di-ili triaza dinezasićenog prstena)karbonil/guanidin derivati za tretiranje ishemije

Also Published As

Publication number Publication date
AP2002002651A0 (en) 2002-12-31
BR0110268A (pt) 2003-12-30
BG107139A (bg) 2003-07-31
HRP20020851A2 (en) 2005-02-28
MY133842A (en) 2007-11-30
EA004882B1 (ru) 2004-08-26
JP2003531900A (ja) 2003-10-28
YU79602A (en) 2006-05-25
GT200100064A (es) 2002-03-22
IL152075A0 (en) 2003-05-29
CR6797A (es) 2004-05-17
MXPA02010600A (es) 2003-03-10
PL357765A1 (pl) 2004-07-26
CN1426404A (zh) 2003-06-25
IS6567A (is) 2002-09-24
AU2001235896A1 (en) 2001-11-12
CO5221125A1 (es) 2002-11-28
MA26897A1 (fr) 2004-12-20
NO20025132D0 (no) 2002-10-25
PA8513301A1 (es) 2003-09-05
CZ20023408A3 (cs) 2004-01-14
UY26680A1 (es) 2001-12-28
EA200201023A1 (ru) 2003-02-27
AR028375A1 (es) 2003-05-07
NZ521348A (en) 2004-09-24
EP1276737A1 (en) 2003-01-22
CA2407535A1 (en) 2001-11-08
DZ3310A1 (fr) 2001-11-07
PE20011270A1 (es) 2001-12-12
KR20020093079A (ko) 2002-12-12
SV2002000418A (es) 2002-07-03
SK14872002A3 (sk) 2004-03-02
UA73348C2 (en) 2005-07-15
CN1225466C (zh) 2005-11-02
HN2001000042A (es) 2001-07-09
TR200202439T2 (tr) 2003-02-21
WO2001083470A1 (en) 2001-11-08
HUP0300651A2 (hu) 2003-07-28
IS6588A (is) 2002-10-21
ZA200208605B (en) 2003-10-24
EE200200615A (et) 2004-04-15
OA12256A (en) 2003-11-06
TNSN01065A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
DE60101714D1 (de) Wärmetauscher
DE50100984D1 (de) Plattenwärmetauscher
FI20001860L (fi) Levyrakenteinen lämmönvaihdin
DE60012822D1 (de) Wärmetauscher
DE60109107D1 (de) Plattenwärmetauscher
DE60138964D1 (de) Wärmetauscher
DE69911131D1 (de) Wärmetauscher
DE60116596D1 (de) Wärmetauscher
DE60138767D1 (de) Wärmetauscher
ITMI20002039A0 (it) Scambiatore di calore
DE60023394D1 (de) Wärmetauscher
DE10083636T1 (de) Wärmetauscher
DE60115565D1 (de) Wärmetauscher
DK1038147T3 (da) Pladevarmeveksler
NO20025132D0 (no) Natrium-hydrogen-byttertype 1-inhibitor (NHE-1)
DE69824454D1 (de) Wärmetauscher
FI20002454L (fi) Lämmönsiirrin
DE60006813D1 (de) Wärmetauscher
ITMI20001583A0 (it) Scambiatore di calore
DE59905017D1 (de) Wärmeübertrager
NO20021821D0 (no) Natrium-hydrogen utvekslingstype 1 inhibitor krystaller
DE60102847D1 (de) Wärmetauscher
FI20002648L (fi) Lämmönsiirrin
FI981909L (fi) Lämmönsiirrin
ATA200698A (de) Wärmetauscher

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application